

## **Aligos Therapeutics to Present Program Updates at the 32nd Conference of the Asian Pacific Association for the Study of the Liver**

SOUTH SAN FRANCISCO, Calif., Feb. 14, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in NASH and viral diseases, today announced that the company will deliver several oral and poster presentations at the 32<sup>nd</sup> Conference of the Asian Pacific Association for the Study of the Liver (APASL), being held Feb 15 – 19 in Taipei, Taiwan at the Taipei International Convention Center. Aligos will present data for ALG-055009, its THR- $\beta$  agonist in development for nonalcoholic steatohepatitis (NASH), as well as for several clinical and nonclinical investigational agents from its chronic hepatitis B (CHB) portfolio.

“At this year’s APASL meeting, we look forward to presenting data from several of our ongoing programs including ALG-055009, our thyroid hormone receptor-beta (THR- $\beta$ ) agonist in development for NASH for which we are conducting Phase 2-enabling activities to enable a Phase 2 filing by the end of this year,” said Lawrence Blatt, Ph.D., MBA, CEO and Chairman of the Board at Aligos. “In addition, we are pleased to show exciting data for our CAM-E, ALG-000184, demonstrating notable reductions in HBsAg levels in patients with HBeAg-positive CHB.”

Presentation details are as follows. Posters will be available for viewing throughout the conference.

### **NASH program**

#### Poster presentation

**Title:** Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Single and Multiple Ascending Oral Doses of ALG-055009, a Thyroid Hormone Receptor Beta (THR- $\beta$ ) Agonist for the Treatment of Non-Alcoholic Steatohepatitis (NASH), in Healthy Volunteers and Subjects with Hyperlipidaemia

**Presenter:** Hakim Charfi, M.D.

**Poster number:** PH-025

### **Chronic hepatitis B program**

#### Oral presentations

**Title:** The Capsid Assembly Modulator ALG-000184 Dosed for 28 Days Was Well Tolerated and Rapidly Reduced Viral Markers in Subjects with Chronic Hepatitis B, Including HBsAg in a Subset of HBeAg Positive Subjects with Elevated Baseline ALT

**Presenter:** Ed Gane, MBChB, M.D.

**Presentation date/time:** Thursday, February 16, 14:40 – 14:55 Taipei Standard Time (TST)

**Presentation location:** 3F North Lounge

**Session title:** HBV (Clinical) and HCV

**Presentation number:** FP03-16

**Title:** ALG-000184, a Capsid Assembly Modulator, Demonstrates Superior Antiviral Activity in Combination with Entecavir Compared to Entecavir in HBeAg Positive Subjects with Chronic Hepatitis B infection

**Presenter:** Jinlin Hou, M.D.

**Presentation date/time:** Thursday, February 16, 14:55 – 15:10 TST

**Presentation location:** 3F North Lounge

**Session title:** HBV (Clinical) and HCV

**Presentation number:** FP03-17

**Title:** A Preclinical Profile of ALG-125755, a GalNAc-siRNA Targeting HBV

**Presenter:** Jin Hong, Ph.D.

**Presentation date/time:** Saturday, February 18, 11:35 – 11:50 TST

**Presentation location:** 3F South Lounge

**Session title:** HBV (Basic)

**Presentation number:** FP11-59

#### Poster presentations

**Title:** Effect of the Capsid Assembly Modulator (CAM) ALG-000184 on HBsAg Levels in Subjects with HBeAg Positive Chronic Hepatitis B (CHB)

**Presenter:** Jinlin Hou, Ph.D.

**Poster number:** PC-019

**Title:** Preclinical Antiviral, Pharmacological and Toxicological Characteristics of ALG-000184, a Prodrug of the Novel HBV Capsid Assembly Modulator ALG-001075

**Presenter:** Andreas Jekle, Ph.D.

**Poster number:** PB-007

**Title:** Safety, Tolerability and Pharmacokinetics (PK) of Single Ascending Doses of ALG-125755, a GalNAc-Conjugated Small Interfering RNA (siRNA), in Healthy Volunteers (HV)

**Presenter:** Ed Gane, MBChB, M.D.

**Poster number:** PPB-043

**Title:** Discovery of a Liver-Targeted PD-L1 Small Molecule Inhibitor for the Treatment of Chronic Hepatitis B and Liver Cancer

**Presenter:** Heleen Roose, Ph.D.  
**Poster number:** PB-010

### **About Aligos**

Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of liver diseases and viral infections. Aligos is leveraging its expertise in liver and infectious diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH) and for the discovery and development of targeted antiviral therapies for coronaviruses. Aligos' strategy is to harness the deep expertise and decades of drug development experience its team has in liver and infectious disease, to rapidly advance its pipeline of potentially best-in-class molecules.

### **Forward-Looking Statement**

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered "forward-looking statements," including without limitation, statements with respect to ALG-055009, Aligos' plan to complete its ongoing Phase 1 study and Phase 2-enabling activities, including GLP toxicology studies, to enable a Phase 2 filing by the end of this year. Forward-looking statements are typically, but not always, identified by the use of words such as "may," "will," "would," "believe," "intend," "plan," "anticipate," "estimate," "expect," and other similar terminology indicating future results. Such forward looking statements are subject to substantial risks and uncertainties that could cause our development programs, future results, performance, or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include without limitation risks and uncertainties inherent in the drug development process, including Aligos' clinical-stage of development, the process of designing and conducting clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, Aligos' ability to successfully establish, protect and defend its intellectual property, other matters that could affect the sufficiency of Aligos' capital resources to fund operations, reliance on third parties for manufacturing and development efforts, changes in the competitive landscape and the effects on our business of the worldwide COVID-19 pandemic and the ongoing conflict between Russia and Ukraine. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Aligos in general, see Aligos' Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 2, 2022 and its future periodic reports to be filed or submitted with the Securities and Exchange Commission. Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.

### **Media Contact**

Amy Jobe, Ph.D.  
LifeSci Communications  
+1 315 879 8192  
ajobe@lifescicomms.com

### **Investor Contact**

Corey Davis, Ph.D.  
LifeSci Advisors  
+1 212 915 2577  
cdavis@lifesciadvisors.com